Stempoint Capital’s Dianthus Therapeutics DNTH Stock Holding History

Stempoint Capital’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.6M	Buy	200,851 +115,349	+135%	+$10.1M	3.37%	6
2026 Q1	$7.18M	Buy	85,502 +6,218	+8%	+$360K	1.37%	27
2025 Q4	$3.27M	Buy	79,284 +37,902	+92%	+$1.47M	0.56%	48
2025 Q3	$1.63M	Buy	+41,382	New	+$1.06M	0.33%	54
2024 Q2	–	Sell	-43,456	Closed	-$1.3M	–	56
2024 Q1	$1.3M	Buy	+43,456	New	+$945K	0.34%	42

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Stempoint Capital's DNTH Position: Q2 2026 in Review

Stempoint Capital increased its Dianthus Therapeutics (DNTH) stake by 135% in Q2 2026, buying an estimated $10.1M and bringing the position to 200,851 shares worth $19.6M. The position accounts for 3.37% of the portfolio, ranked #6.

Stempoint Capital first reported a position in DNTH in Q1 2024 and has held it in 5 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Stempoint Capital held 200,851 shares of Dianthus Therapeutics worth $19.6M as of Q2 2026.
Stempoint Capital bought 115,349 Dianthus Therapeutics shares in Q2 2026, an estimated $10.1M.
Dianthus Therapeutics made up 3.37% of Stempoint Capital's portfolio in Q2 2026, its #6 holding.
Stempoint Capital first reported a position in Dianthus Therapeutics in Q1 2024 and has held it in 5 quarters since.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.